Epilepsy: key endpoint results by drug

The key endpoints of Epilepsy trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Epilepsy page.

Seizure frequency, % change

Seizure frequency, % change in Epilepsy: 7 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brivaracetam-53.0%-24.4%−28.750 mg/day · wk 7 · n 52NCT00175825 Phase 2, secondary
Cannabidiol (Epidiolex)-41.2%-13.7%−27.520 mg/kg/day · wk 14.14 · n 86NCT02224690 Phase 3, secondary
Cenobamate-71.9%-39.6%−32.3wk 22 · n 85NCT03678753 Phase 3, primary
Ganaxolone-7.5%13.6%−21.1wk 4 · n 64NCT05323734 Phase 3, primary
Lamotrigine75.4%32.1%+43.3wk 19 · n 69NCT00104416 Phase 3, primary
Perampanel-34.5%-20.9%−13.512 mg · wk 19 · n 133NCT00699972 Phase 3, primary
Zonisamide (Zonegran)-48.4%-26.6%−21.8100 mg · wk 16 · n 111NCT00327717 Phase 3, primary

Drugs checked with no result here: 28 not reported, 15 not posted, 15 trial running.

50% responder rate

50% responder rate in Epilepsy: 8 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brivaracetam36%20%+16100 mg/day · wk 12 · n 100NCT00490035 Phase 3, secondary
Cenobamate57.8%21.7%+36.1200 mg/Day · wk 18 · n 109NCT01866111 Phase 2, secondary
Eslicarbazepine acetate30.6%31%−0.4n 134NCT00988156 Phase 3, primary
Ganaxolone18.8%12.3%+6.5wk 16 · n 64NCT05323734 Phase 3, secondary
natalizumab31.3%17.6%+13.7300 mg · wk 24 · n 32NCT03283371 Phase 2, secondary
Oxcarbazepine (Oxtellar XR)50%34%+162400 mg/day · wk 16 · n 109NCT00772603 Phase 3, secondary
Pregabalin40.6%22.6%+1810 mg/kg/Day or 14 mg/kg/Day · wk 12 · n 97NCT01389596 Phase 3, secondary
Zonisamide (Zonegran)48.6%34.9%+13.7100 mg · wk 16 · n 111NCT00327717 Phase 3, secondary

Drugs checked with no result here: 15 not posted, 27 not reported, 15 trial running.

Seizure freedom

Seizure freedom in Epilepsy: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Brivaracetam86.7%73.3% (Lorazepam (LZP))—100 mg · n 15NCT03021018 Phase 2, secondary
Ganaxolone0%2.2%−2.2wk 10 · n 95NCT00465517 Phase 2, secondary
Midazolam (Nayzilam)54.8%38.7%+16.1wk 0.04 · n 31NCT01999777 Phase 3, primary
natalizumab0%2.9%−2.9300 mg · wk 24 · n 31NCT03283371 Phase 2, secondary
Perampanel14.3%50% (Standard of Care)—wk 52 · n 7NCT04497142 Phase 1/2, secondary
Zonisamide (Zonegran)1.8%2.8%−1100 mg · wk 16 · n 111NCT00327717 Phase 3, secondary

Drugs checked with no result here: 18 not posted, 26 not reported, 15 trial running.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 65 approved or late-stage drugs with a featured trial in Epilepsy were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.